{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:40Z","timestamp":1791245200958,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive, and its cost-effectiveness compared with other prevention strategies remains unknown. We conducted a trial\u2013based economic evaluation from the Australian health care system perspective to estimate the 12-month cost-effectiveness of prophylactic Ig vs prophylactic antibiotics in 63 adults with HGG and hematological malignancies participating in the RATIONAL feasibility trial. Two analyses were conducted: (1) cost-utility analysis to assess the incremental cost per quality-adjusted life year (QALY) gained; and (2) cost-effectiveness analysis to assess the incremental cost per serious infection prevented (grade \u22653) and per any infection (any grade) prevented. Over 12\u00a0months, the total cost per patient was significantly higher in the Ig group than in the antibiotic group (mean difference, AU$29\u2009140; P\u00a0&amp;lt; .001). Most patients received IVIg, which was the main cost driver; only 2 patients in the intervention arm received subcutaneous Ig. There were nonsignificant differences in health outcomes. Results showed Ig was more costly than antibiotics and associated with fewer QALYs. The incremental cost-effectiveness ratio of Ig vs antibiotics was AU$111\u2009262 per serious infection prevented, but Ig was more costly and associated with more infections when all infections were included. On average and for this patient population, Ig prophylaxis may not be cost-effective compared with prophylactic antibiotics. Further research is needed to confirm these findings in a larger population and considering longer-term outcomes. The trial was registered at the Australian and New Zealand Clinical Trials Registry as #ACTRN12616001723471.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012047","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:59:53Z","timestamp":1710446393000},"page":"2259-2267","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-5392","authenticated-orcid":false,"given":"Sara","family":"Carrillo de Albornoz","sequence":"first","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-7559","authenticated-orcid":false,"given":"Alisa M.","family":"Higgins","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-2531","authenticated-orcid":false,"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Irving","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fanning","sequence":"additional","affiliation":[{"name":"2Centre for Health Economics, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3645-7988","authenticated-orcid":false,"given":"Robert","family":"Weinkove","sequence":"additional","affiliation":[{"name":"3Te Rerenga Ora Wellington Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand"},{"name":"4Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand"},{"name":"5Department of Pathology & Molecular Medicine, University of Otago Wellington, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Crispin","sequence":"additional","affiliation":[{"name":"6Canberra Hospital, Canberra, Australia"},{"name":"7School of Medicine and Psychology, Australian National University, Canberra, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dendle","sequence":"additional","affiliation":[{"name":"8Monash Infectious Diseases, Monash Health, Melbourne, Australia"},{"name":"9School of Clinical Sciences, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gilbertson","sequence":"additional","affiliation":[{"name":"10Department of Clinical Haematology, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-5203","authenticated-orcid":false,"given":"Anna","family":"Johnston","sequence":"additional","affiliation":[{"name":"11Royal Hobart Hospital, Hobart, Australia"},{"name":"12University of Tasmania, Hobart, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastazia","family":"Keegan","sequence":"additional","affiliation":[{"name":"13PathWest Laboratory Medicine, King Edward Memorial Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-6395","authenticated-orcid":false,"given":"Dominic","family":"Pepperell","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Fiona Stanley Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humphrey","family":"Pullon","sequence":"additional","affiliation":[{"name":"15Department of Haematology, Waikato Hospital, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-8625","authenticated-orcid":false,"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"16Central Clinical School, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"van Tonder","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"17Concord Repatriation General Hospital, Sydney, Australia"},{"name":"18University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-1827","authenticated-orcid":false,"given":"Neil","family":"Waters","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5394","authenticated-orcid":false,"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Weston","sequence":"additional","affiliation":[{"name":"19Sunshine Coast University Hospital, Sunshine Coast, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Orla","family":"Morrissey","sequence":"additional","affiliation":[{"name":"16Central Clinical School, Monash University, Melbourne, Australia"},{"name":"20Department of Infectious Diseases, Alfred Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-2340","authenticated-orcid":false,"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7185","authenticated-orcid":false,"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"10Department of Clinical Haematology, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"2024051415214172900_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2024051415214172900_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ejh.13078","article-title":"A\u00a0French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency","volume":"101","author":"Benbrahim","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"2024051415214172900_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol Oncol"},{"key":"2024051415214172900_bib4","unstructured":"European Medicines Agency\n          . Guideline on Core SmPC for Human Normal Immunoglobulin for Intravenous Administration (IVIg). 2018. Accessed 7 April 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-5_en.pdf."},{"key":"2024051415214172900_bib5","unstructured":"UK Department of Health\n          . Clinical Guidelines for Immunoglobulin Use, Update to 2nd Edition. 2011. Accessed 7 April 2022. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216671\/dh_131107.pdf."},{"key":"2024051415214172900_bib6","unstructured":"BloodStar\n          . Criteria for Clinical Use of Immunoglobulin in Australia: Acquired Hypogammaglobulinaemia Secondary to Haematological Malignancies, or Post-Haemopoietic Stem Cell Transplantation (HSCT). Accessed 7 April 2022. https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2621."},{"issue":"1","key":"2024051415214172900_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024051415214172900_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1744666X.2020.1807328","article-title":"A\u00a0systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants","volume":"16","author":"Monle\u00f3n Bonet","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"2024051415214172900_bib9","first-page":"Cd006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"2008","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2024051415214172900_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tracli.2020.12.005","article-title":"Review of indications for immunoglobulin (IG) use: narrowing the gap between supply and demand","volume":"28","author":"Brand","year":"2021","journal-title":"Transfus Clin Biol"},{"key":"2024051415214172900_bib11","unstructured":"National Blood Authority\n          . National Blood Authority National Report on the Issue and Use of Immunoglobulin (Ig) Annual Report 2017-18. 2018. Accessed 8 September 2023. https:\/\/www.blood.gov.au\/data-analysis-reporting#Report-on-the-Issue-and-Use-of-Immunoglobulin."},{"key":"2024051415214172900_bib12","unstructured":"National Blood Authority\n          . Ig Usage Data and Statistics \u2013 May 2023. Accessed 8 September 2023. https:\/\/www.blood.gov.au\/ig-usage-data-and-statistics."},{"issue":"6","key":"2024051415214172900_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","article-title":"Global immunoglobulin supply: steaming towards the iceberg?","volume":"20","author":"Prevot","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1-2","key":"2024051415214172900_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000453662","article-title":"A\u00a0cost-effective approach to the diagnosis and management of acute infectious encephalitis","volume":"77","author":"Misra","year":"2017","journal-title":"Eur Neurol"},{"issue":"2","key":"2024051415214172900_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamapediatrics.2021.4583","article-title":"Cost utility of lifelong immunoglobulin replacement therapy vs hematopoietic stem cell transplant to treat agammaglobulinemia","volume":"176","author":"Sun","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2024051415214172900_bib16","doi-asserted-by":"crossref","first-page":"108419","DOI":"10.1016\/j.clim.2020.108419","article-title":"Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): a retrospective multicenter study","volume":"215","author":"Legendre","year":"2020","journal-title":"Clin Immunol"},{"key":"2024051415214172900_bib17","unstructured":"National Blood Authority\n          . Annual Report 2021-2022. 2022. Accessed 13 September 2023. https:\/\/blood.gov.au\/sites\/default\/files\/NBA0861%20%20NBA%20Annual%20Report%20202122%20-%20WCAG.pdf."},{"issue":"S1","key":"2024051415214172900_bib18","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1017\/S0266462323001113","article-title":"OP95 a systematic review of the cost and cost effectiveness of immunoglobulin treatment in patients with hematological malignancies","volume":"39","author":"De Albornoz","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"2024051415214172900_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"2024051415214172900_bib20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011231","article-title":"Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to haematological malignancy","author":"McQuilten","year":"15  2023","journal-title":"Blood Adv"},{"key":"2024051415214172900_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.socscimed.2018.06.009","article-title":"Life satisfaction, QALYs, and the monetary value of health","volume":"211","author":"Huang","year":"2018","journal-title":"Soc Sci Med"},{"key":"2024051415214172900_bib22","unstructured":"Commonwealth of Australia\n          . Availability of New, Innovative and Specialist Cancer Drugs in Australia. Chapter 3. Affordable Access-Assessing Cost-Effectiveness. 2015. Accessed 7 February 2024. https:\/\/www.aph.gov.au\/Parliamentary_Business\/Committees\/Senate\/Community_Affairs\/Cancer_Drugs\/Report."},{"key":"2024051415214172900_bib23","doi-asserted-by":"crossref","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"2024051415214172900_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40273-023-01243-0","article-title":"The use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia","volume":"41","author":"Norman","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2024051415214172900_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40273-017-0582-5","article-title":"Australian utility weights for the EORTC QLU-C10D, a multi-attribute utility instrument derived from the cancer-specific quality of life questionnaire, EORTC QLQ-C30","volume":"36","author":"King","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2024051415214172900_bib26","unstructured":"Independent Health and Aged Care Pricing Authority\n          . National Hospital Cost Data Collection (NHCDC) Public Hospitals Report 2019-20. 2022. Accessed 13 September 2023. https:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-hospitals-report-2019-20."},{"key":"2024051415214172900_bib27","unstructured":"Wyndham\n              A\n            , VoganA, NewtonS, SchubertC. Immunoglobulin for Acquired Hypogammaglobulinaemia Secondary to Haematological Malignancies, or Post-Haemopoietic Stem Cell Transplantation (HSCT). MSAC. 2019. Accessed 9 November 2022. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/1565-public."},{"key":"2024051415214172900_bib28","unstructured":"Blood Matters\n          . Consultation Paper on the Pricing Framework for Australian Public Hospital Services 2023-24. 2022. Accessed 13 September 2023. https:\/\/www.ihacpa.gov.au\/sites\/default\/files\/2022-09\/blood_matters_program_national_bloody_authority.pdf."},{"key":"2024051415214172900_bib29","unstructured":"Australian Bureau of Statistics\n          . Consumer Price Index, Australia. Accessed 13 September 2023. https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia\/mar-quarter-2023."},{"issue":"7","key":"2024051415214172900_bib30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jval.2020.04.1825","article-title":"EQ-5D-derived health state utility values in hematologic malignancies: a catalog of 796 utilities based on a systematic review","volume":"23","author":"Golicki","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"2024051415214172900_bib31","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival","volume":"56","author":"Kosmas","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2024051415214172900_bib32","doi-asserted-by":"crossref","first-page":"e0247717","DOI":"10.1371\/journal.pone.0247717","article-title":"Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: real life evidence as compared to primary antibody deficiencies","volume":"16","author":"Cinetto","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"2024051415214172900_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000443360","article-title":"Effects of antibiotics on gut microbiota","volume":"34","author":"Lange","year":"2016","journal-title":"Dig Dis"},{"issue":"10325","key":"2024051415214172900_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"2024051415214172900_bib35","doi-asserted-by":"crossref","first-page":"e0285170","DOI":"10.1371\/journal.pone.0285170","article-title":"The economic burden of antibiotic resistance: a systematic review and meta-analysis","volume":"18","author":"Poudel","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"2024051415214172900_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11096-018-00781-4","article-title":"Infectious diseases physician attitudes to long-term antibiotic use","volume":"41","author":"Kiss","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"2024051415214172900_bib37","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/jac\/dky174","article-title":"Life-long antimicrobial therapy: where is the evidence?","volume":"73","author":"Lau","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"2024051415214172900_bib38","unstructured":"National Blood Authority\n          . Evaluate and Develop Options to Improve Access to Subcutaneous Immunoglobulin (SCIg). Final Report. 2023. Accessed 3 January 2024. https:\/\/blood.gov.au\/system\/files\/documents\/HealthConsult%20NBA%20SCIg%20Service%20Model%20FINAL%20Report.pdf."},{"issue":"1","key":"2024051415214172900_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","article-title":"Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency","volume":"23","author":"Martin","year":"2013","journal-title":"Transfus Med"},{"issue":"5","key":"2024051415214172900_bib41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10875-016-0288-z","article-title":"Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an Interprofessional Drug Therapy Management Program","volume":"36","author":"Perraudin","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"2024051415214172900_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1710-1492-10-23","article-title":"Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous\u00a0immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada","volume":"10","author":"Gerth","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"2024051415214172900_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13223-022-00735-6","article-title":"Economic impact of self-administered subcutaneous versus clinic-administered\u00a0intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study","volume":"18","author":"Ritchie","year":"2022","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2259\/2224876\/blooda_adv-2023-012047-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2259\/2224876\/blooda_adv-2023-012047-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:22:48Z","timestamp":1715700168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2259\/515320\/Economic-evaluation-immunoglobulin-vs-prophylactic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012047","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}